MTOR and common variable immunodeficiency: Along with drugs of well-established positions in the therapy of CVID complications, such as the mammalian target of rapamycin (mTOR) signaling inhibitor sirolimus for GLILD, novel immunosuppressive and immunomodulating agents promote and facilitate more effective treatment strategies to protect patients from multisystemic immune dysregulation and organ failure.